Data indicate that the LP.8.1-adapted COVID-19 vaccine confers improved immune response against currently dominant and emerging sublineages – including the XFG and NB.1.8.1 variants1 – compared to ...
Findings from this trial reinforce the preclinical data supporting the approval of the LP.8.1-adapted COVID-19 vaccine for the 2025-2026 season. Topline results were announced from a phase 3 trial ...
Thursday, the FDA granted emergency use authorization (EUA) for updated mRNA COVID-19 vaccines (2024-2025 formula) to include a monovalent (single) component that corresponds to the Omicron variant KP ...
(RTTNews) - Pfizer Canada ULC and BioNTech SE (BNTX) announced that Health Canada has authorized the LP.8.1 variant adapted COMIRNATY COVID-19 vaccine for individuals aged 6 months and older. The ...
A messenger RNA combination vaccine that Pfizer and BioNTech are developing for both Covid-19 and influenza posted mixed results in a pivotal study, meeting just one of the two main goals assessing ...
BioNTech co-founders Dr. Ugur Sahin and Dr. Ozlem Tureci in its headquarters in Germany on Jan. 3.Photograph by Dina Litovsky—Redux for TIME “No!” The doctor snapped. “Look at me!” I had been staring ...
The new updated Comirnaty Pfizer COVID mRNA vaccine is seen here next to the Fluzone H,D. influenza vaccine at a Walgreens pharmacy in Torrance, Caifornia, on September 5, 2024. (Genaro Molina/Los ...
On August 22, Moderna announced that FDA approved its supplemental Biologics License Application (“sBLA”) for a new formula of their COVID-19 vaccine, SPIKEVAX®, for individuals 12 years old and above ...
Aug 6 (Reuters) - The University of Pennsylvania has sued German biotechnology firm BioNTech (22UAy.DE), opens new tab in Pennsylvania federal court, accusing the company of underpaying royalties for ...
Upon authorization by the European Commission (EC), the Omicron KP.2-adapted COVID-19 vaccine will be available for individuals 6 months of age and older Data demonstrate that the Omicron KP.2-adapted ...
The CHMP’s recommendation will be reviewed by the European Commission (EC), which is expected to make its final decision soon. Pfizer and BioNTech have already initiated manufacturing of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results